Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Benoit You"'
Autor:
Alicja Puszkiel, Benoit You, Léa Payen, Jonathan Lopez, Jérôme Guitton, Pascal Rousset, Juliette Fontaine, Julien Péron, Denis Maillet, Sophie Tartas, Nathalie Bonnin, Veronique Trillet-Lenoir, Olivier Colomban, Diane Augu-Denechere, Gilles Freyer, Michel Tod
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:413-425
Autor:
Romain Varnier, Alicja Puszkiel, Michel Tod, Sara Calattini, Lea Payen, Jonathan Lopez, Jérome Guitton, Vérane Schwiertz, Juliette Fontaine, Julien Peron, Denis Maillet, Sophie Tartas, Nathalie Bonnin, Olivier Colomban, Diane Augu-Denechere, Gilles Freyer, Benoit You
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:361-373
Autor:
Xinhui Chen, Nicolas Isambert, Rafael López‐López, Monica Giovannini, Nathalie Pognan, Shruti Kapoor, Michelle Quinlan, Benoit You, Xiaoming Cui, Gholamreza Rahmanzadeh, Morten Mau‐Sorensen
Publikováno v:
Chen, X, Isambert, N, López-López, R, Giovannini, M, Pognan, N, Kapoor, S, Quinlan, M, You, B, Cui, X, Rahmanzadeh, G & Mau-Sorensen, M 2023, ' Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours ', British Journal of Clinical Pharmacology, vol. 89, no. 3, pp. 1046-1055 . https://doi.org/10.1111/bcp.15544
Background: Preclinical studies showed that capmatinib reversibly inhibits cytochrome P450 (CYP) 3A4 and CYP1A2 in a time-dependent manner. In this study, we evaluated the effect of capmatinib on the exposure of sensitive substrates of CYP3A (midazol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e751618123039bf7c0a8151dbb589a3e
https://curis.ku.dk/portal/da/publications/effect-of-capmatinib-on-the-pharmacokinetics-of-substrates-of-cyp3a-midazolam-and-cyp1a2-caffeine-in-patients-with-metdysregulated-solid-tumours(72512f3f-33d1-4b5e-974b-4b8e0ef1d394).html
https://curis.ku.dk/portal/da/publications/effect-of-capmatinib-on-the-pharmacokinetics-of-substrates-of-cyp3a-midazolam-and-cyp1a2-caffeine-in-patients-with-metdysregulated-solid-tumours(72512f3f-33d1-4b5e-974b-4b8e0ef1d394).html
Autor:
Manon Reda, Pauline Macaire, Hélène Bellio, Lionel Uwer, Silvia Ilie, Véronique Lorgis, Audrey Hennequin, Sylvain Ladoire, Emilie Rederstorff, Pierre Fumoleau, Nicolas Isambert, Nathalie Bonnin, Benoit You, Gilles Freyer, Isabelle Desmoulins, Antonin Schmitt
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:197-208
Granulocyte colony-stimulating factors (G-CSF) are commonly given to limit chemotherapy-induced neutropenia, but, in case of weekly chemotherapy such as eribulin, their administration schedules remain empirical.This pharmacokinetic/pharmacodynamic (P
Autor:
Michel Tod, Pierre-Adrien Bolze, Olivier Colomban, Rémi Tod, Benoit You, Michael J. Seckl, Gilles Freyer, R. Osborne, Kathleen Dekeister, Touria Hajri, François Golfier, Jean-Pierre Lotz, Jérôme Massardier
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:15-24
In a low-risk gestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX), the modeled hCG (human chorionic gonadotropin) residual concentration (hCGres), calculated with NONMEM program® (NM) during the first 50 treatment days, is a pr
Autor:
Aurélien Marabelle, Christophe Massard, Fanny Pommeret, Caroline Brard, Patricia Pautier, Angelo Paci, Joseph Ciccolini, Alexandra Leary, Anne Floquet, Lauriane Eberst, Catherine Genestie, Emeline Colomba, Corinne Balleyguier, Rastilav Bahleda, Benoit You, Judith Michels, François Ghiringhelli, Jean-Sebastien Frenel
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A382-A382
BackgroundThere is a medical need in platinum resistant ovarian cancer patients. Median progression-free survival (PFS) is 3.4 months with chemotherapy and 6.7 months with chemotherapy-bevacizumab combination regimens.1 RECIST overall response rate (
Autor:
Aurélien Millet, Guillaume Picard, Dorothée Lebert, Philippe Ceruse, Jérôme Guitton, Benoit You
Publikováno v:
Therapeutic drug monitoring. 41(4)
Background Cetuximab (CTX) is a chimeric IgG1 Kappa monoclonal antibody used to treat head and neck cancer and colorectal cancer. Previous clinical studies indicated that the pharmacokinetics of CTX influences patient survival. Thus, individualizing
Autor:
Karthick Vishwanathan, Benoit You, Martin Johnson, Jaime Feliu Batlle, Hal Galbraith, John Sarantopoulos, R. Donald Harvey, Enrique Grande, Suresh S. Ramalingam, Karen So, Helen Mann
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 369(2)
Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), undergoes significant hepatic elimination. In this phase 1 study, we assessed the effects of mild and moderate hepatic impairment on the pharmacokinetics (PK) of
Autor:
Benoit You, Gilles Freyer, Athanassios Iliadis, Christophe Meille, Jérôme Guitton, Dominique Barbolosi, Emilie Henin
Publikováno v:
Breast Cancer Research and Treatment. 156:331-341
The MODEL1 trial is the first model-driven phase I/II dose-escalation study of densified docetaxel plus epirubicin administration in metastatic breast cancer patients, a regimen previously known to induce unacceptable life-threatening toxicities. The
Autor:
Gilles Freyer, Benoit You, Jérôme Guitton, Pierre-Jean Valette, Francoise Berger, Philippe A. Cassier, Thibaud Lefort, Mévidette El-Madani, Joël Lachuer, Catherine Barrois, K. Slimane, Michel Tod, Claire Rodriguez-Lafrasse, Emilie Henin
Publikováno v:
Future Oncology. 11:1511-1518
ABSTRACT Optimal development of targeted drug combinations is one of the future challenges to be addressed. Computerization and mathematical models able to describe biological phenomena and to simulate the effects of changes in experimental condition